Free Newsletter
Shire faces battle against ADHD generics
Free newsletter via e-mail
Tools
Shire, the maker of ADHD drugs Adderall XR and Vyvanse, had an excellent Q1 but now faces a challenge: Its two top products are threatened by a generic that Teva brought to market on April 2, BNet Pharma reports. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: